Costs and benefits of influenza vaccination: more evidence, same challenges

BMC Public Health

Giovanni Rezza¹  Bruno Christian Ciancio² 

[1] Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Roma, Italy;European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

关键词: Cost;    Vaccine effectiveness;    Influenza burden;   

Others  :  1128732
DOI  :  10.1186/1471-2458-14-818

 received in 2014-07-03, accepted in 2014-07-29,  发布年份 2014

【 摘 要 】

Seasonal influenza vaccination coverage in most EU/EEA remains suboptimal. Providers’ and users’ confidence in influenza vaccines is undermined by reports of moderate to low vaccine effectiveness and by the lack of solid evidence on disease burden. A study from Preaud and co. indicates that even with current levels of vaccine effectiveness, increasing vaccination coverage would significantly reduce disease burden and health cost. The results of the study should be interpreted cautiously because some of the assumptions are not generalizable or are imprecise, especially those on vaccine coverage, disease burden and health cost. Increasing vaccination coverage in EU/EEA countries is very challenging. Multifaceted approaches and country specific strategies are needed to address vaccine hesitancy in health care workers and in the population, and to manage organisational and financial obstacles. One key element for increasing vaccination coverage is the development of better influenza vaccines, e.g. vaccines that are more effective, provide longer lasting immunity and do not require annual administration. Vaccine producers should consider this as the highest research priority in the field of influenza vaccine development.

【 授权许可】

   
2014 Ciancio and Rezza; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Commissions of the European Communities: Council Recommendation of 22 December 2009 on seasonal influenza vaccination (2009/1019/EU). Brussels: Commission of the European Communities; 2009. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF webcite
• [2]Mereckiene J, Cotter S, Nicoll A, Lopalco P, Noori T, Weber J, D'Ancona F, Levy-Bruhl D, Dematte L, Giambi C, Valentiner-Branth P, Stankiewicz I, Appelgren E, D OF: Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2014, 19(16):20780.
• [3]Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, Shupo F, Samson SI: Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health 2014, 14(1):813. BioMed Central Full Text
• [4]Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, Petrie JG, Lofthus G, Meece JK, Williams JV, Berman L, Breese Hall C, Monto AS, Griffin MR, Belongia E, Shay DK, Network USF-V: Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2012, 55(7):951-959.
• [5]Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, Stefanoff P, Nunes B, Pitigoi D, Larrauri A, Daviaud I, Horvath JK, O'Donnell J, Seyler T, Paradowska-Stankiewicz IA, Pechirra P, Ivanciuc AE, Jimenez-Jorge S, Savulescu C, Ciancio BC, Moren A: I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PloS one 2011, 6(11):e27622.
• [6]Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, Pitigoi D, Rizzo C, Rebolledo J, Paradowska-Stankiewicz I, Jimenez-Jorge S, Horvath JK, Daviaud I, Guiomar R, Necula G, Bella A, O'Donnell J, Gluchowska M, Ciancio BC, Nicoll A, Moren A: Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2013., 18(5)
• [7]Ehrenstein BP, Hanses F, Blaas S, Mandraka F, Audebert F, Salzberger B: Perceived risks of adverse effects and influenza vaccination: a survey of hospital employees. European journal of public health 2010, 20(5):495-499.
• [8]Kelly C, Dutheil F, Haniez P, Boudet G, Rouffiac K, Traore O: Chamoux A: [Analysis of motivations for antiflu vaccination of the Clermont-Ferrand University Hospital staff]. Medecine et maladies infectieuses 2008, 38(11):574-585.
• [9]Wicker S, Rabenau HF, Doerr HW, Allwinn R: Influenza vaccination compliance among health care workers in a German university hospital. Infection 2009, 37(3):197-202.
• [10]Dedoukou X, Nikolopoulos G, Maragos A, Giannoulidou S, Maltezou HC: Attitudes towards vaccination against seasonal influenza of health-care workers in primary health-care settings in Greece. Vaccine 2010, 28(37):5931-5933.
• [11]Di Giuseppe G, Nobile CG, Marinelli P, Angelillo IF: A survey of knowledge, attitudes, and behavior of Italian dentists toward immunization. Vaccine 2007, 25(9):1669-1675.
• [12]Osterholm MT, Kelley NS, Sommer A, Belongia EA: Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet infectious diseases 2012, 12(1):36-44.
• [13]Rivetti D, Jefferson T, Thomas R, Rudin M, Rivetti A, Di Pietrantonj C, Demicheli V: Vaccines for preventing influenza in the elderly. The Cochrane database of systematic reviews 2006, 3:CD004876.
• [14]Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E: Vaccines for preventing influenza in healthy adults. The Cochrane database of systematic reviews 2010, 7:CD001269.
• [15]Valenciano M, Kissling E, Ciancio BC, Moren A: Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine 2010, 28(46):7381-7388.
• [16]Valenciano M, Ciancio B: I-MOVE: a European network to measure the effectiveness of influenza vaccines. Euro Surveill 2012., 17(39)
• [17]Eurosurveillance Editorial Team: ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe. Euro Surveill 2009., 14(39)
• [18]Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ: Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control 2010, 59(RR-8):1-62.
• [19]European Centre for Disease Prevention and Control: ECDC scientific advice on seasonal influenza vaccination of children and pregnant women. Stockholm: ECDC; 2012. Available from: http://www.ecdc.europa.eu/en/publications/publications/seasonal%20influenza%20vaccination%20of%20children%20and%20pregnant%20women.pdf webcite
• [20]Nicoll A, Sprenger M: Low effectiveness undermines promotion of seasonal influenza vaccine. The Lancet infectious diseases 2013, 13(1):7-9.